2022

julesawalters

MedShr awarded Gold, Silver and Bronze at PM Society Digital Awards 2022

MedShr awarded Gold, Silver and Bronze at PM Society Digital Awards 2022

22 September 2022

  • An innovative platform that specialises in case-based HCP education stood out at this year’s PM Society Digital Awards 
  • MedShr won Gold in the category Healthcare Provider Education, Training and Support, as well as Silver and Bronze awards in other categories 
  • Its success speaks to the value of peer-to-peer learning and effectiveness of case-based education in engaging clinicians globally

Representing a novel approach to medical education, a mobile-first platform that specialises in clinical case-based education took home awards in three categories at the 2022 PM Society Digital Awards ceremony, held on 15 September in London. Standing out from the established communications agencies that make up the usual winners, MedShr secured Gold for HCP Education, Training and Support, Silver for Evolving Campaigns for Success, and Bronze for Building Digital Communities.

“The way that we engage with and support ongoing clinical education has evolved to centre around when and how clinicians prefer to access that information. We built MedShr from that perspective – the app is in doctor’s pockets and it’s all about peer-to-peer learning and the application of knowledge in the real-world,” says Founder and CEO Asif Qasim, who is also a consultant cardiologist and NHS Clinical Director.

Peer-to-peer learning has always been a crucial part of clinical practice, with doctors sharing challenging cases and learnings with one another on various digital platforms. With MedShr, the conversation has moved into a secure, global, clinician-only space that looks and feels like a social media feed – but is inherently about education and real-world application of clinical science and knowledge.

Over 2-million healthcare professionals now use MedShr, from 195 countries and across all clinical specialities. It’s this large global community of professionals that MedShr taps into to identify healthcare challenges, deliver insights and provide highly targeted educational programmes.

The annual PM Society’s Digital Awards reward innovation and effectiveness in digital medical communications programmes from across the healthcare industry. The ceremony brought together over 500 people from the pharmaceutical industry and supporting agencies to highlight the best programmes, tools and campaigns across a range of digital activities. MedShr was amongst 49 finalists and took home three awards.

MedShr’s winning educational programmes

  • Gold for a Global Health programme that reached almost 1-million healthcare professionals with education and training around the management of malaria, Chagas disease, leprosy, sickle cell disease, antimicrobial resistance, and ophthalmology. 
  • Silver for a programme around x-linked hypophosphatemia that reached over 300,000 doctors with education on the rare disease, designed to increase recognition and diagnosis of patients with XLH, and support with disease management. 
  • Bronze for a programme in haemophilia education that leveraged the scale of the platform to create an online group for education and discussion around haemophilia, attracting and engaging an active community of 600 haematologists.

About MedShr

MedShr is a secure, professional app and network for medical professionals to connect and learn through case discussion. Over two million doctors and HCPs use MedShr to discover, discuss and share clinical cases and medical images. The platform’s innovative educational approach puts focus on the application of insights from the latest scientific publications in real-world scenarios. Developed by doctors, for doctors, its speaks to specialists in their language, fostering learning and discussion about the specifics of clinical decision-making and management.

[ENDS]

julesawalters

Gamechanger for medical research – MedShr launches Docsearch

Gamechanger for medical research – MedShr launches Docsearch

21 September, 2022

MedShr is excited to launch MedShr docsearch, an AI-driven platform that analyses published medical evidence and rapidly reviews complex scientific literature. This technology is being put in the hands of clinicians and academics for the first time, exclusively through MedShr.

Described as a game changer for medical research and clinical practice, MedShr docsearch saves hours of research time, explores data in new ways and can improve patient care. The analytical dashboard shows trending concepts, influential authors, clinical trial status and much more. 

Putting Knowledge into the Hands of Physicians 

MedShr docsearch leverages custom technology developed by Dr. Evidence for drug discovery and pharmaceutical research. For the first time, our exclusive partnership puts this knowledge in the hands of physicians around the world.

The partnership integrates Dr.Evidence’s AI-powered medical search engine with the MedShr platform for physicians, HCPs, medical societies, and academics. 

“We are excited about the power that DocSearch puts in the hands of physicians to engage with the published evidence. The real-time AI insights and analysis from MedShr docsearch combined with MedShr case discussion and peer-to-peer learning will have a tremendous impact on clinical practice and patient care,” said MedShr Founder and CEO Asif Qasim, MA PhD FRCP.  

Better Patient Outcomes 

When you type a query into MedShr docsearch, the tool utilizes its powerful natural language processing and machine learning technology to generate evidence-based results within seconds. 

This means physicians and HCPs will no longer have to spend hours using multiple search engines and tools to get the type of analysis possible in MedShr docsearch. With over 40 million biomedical citations, 108 million biomedical relationships and 4.9 million medical concepts, MedShr docsearch turbocharges any PubMed search. Clinicians will be able to better understand published data, from disease symptoms to drug-adverse events, and beyond. The insights will inform and transform interventions for better patient health outcomes. 

“Since the beginning, our vision has been to democratize medical evidence,” said Dr.Evidence CEO Bob Battista, MBA, FRSPH, FRCP Edinburgh. “That starts with getting medical evidence into the hands of physicians and HCPs who interact daily with peers and directly with patients. Combining the power of the MedShr docsearch specialized medical search engine with the expansive reach of MedShr’s HCP-facing platform creates an unprecedented opportunity for putting actionable insights into the hands of physicians and HCPs, and, in turn, helping them deliver better, evidence-based patient care.”  

About MedShr™

MedShr is the world’s leading case discussion platform, connecting nearly two million doctors across 195 countries and supporting digital medical education for hundreds of national and specialist medical societies. In addition to the Trinity Challenge, MedShr has won multiple awards for technology, business and impact including Facebook’s Social Good App of the Year 2016, United Nations World Summit Award 2017, ES SME Award in 2018, London Business Award 2020, and Pharma Marketing Award 2021.  

About Dr.Evidence™ 

Dr.Evidence™ is the leading medical intelligence platform for life sciences companies that enables teams to identify breakthrough insights grounded in the vast universe of published medical information, real-world evidence and proprietary data. It pushes the boundaries of healthcare technology and allows for new possibilities in science, enabling more informed decision-making and faster time-to-market for accelerated impact. 

julesawalters

MedShr reaches milestone of two million members

MedShr reaches milestone of two million members

11 April, 2022

MedShr now connects over 2 million members and more than 200 national and specialist medical societies in our award-winning platform for doctors.

Launched in 2015 by cardiologist Dr Asif Qasim, MedShr was designed to enable doctors around the world to share knowledge, improve patient care and, ultimately, save lives. Enabling compliant case discussion and medical micro-learning, MedShr’s community grew to 10,000 physician members within the first six months, and to 100,000 within the first year. The platform is now used by over two million members. Every week, more than 10,000 physicians join us from all over the world to share knowledge on everything from rare diseases to global health challenges such as malaria.

Dr Asif Qasim, MedShr founder and CEO, said:

“What we know from talking to doctors around the world is that if guidelines tell us what to do, case discussion shows us how to do it – both in terms of drugs, devices and treatments, but also how to apply them to our patients.”

At MedShr, we now have more than 200 medical society partners. They use our platform to deliver medical education and connect their members through secure, private groups. In addition to providing their members with MedShr’s free app for compliant case discussion, medical societies engage their members through multimedia posts, polls, data, webinars, slides and interactive MedShr Learning modules. Our Chief of Growth and Engagement, Janis Pereira, has a message to our medical society partners:

“I want to say a very special thank you to our medical society partners. The work that you do through MedShr is phenomenal. The calibre of the medical education that you’re sharing through MedShr is amazing. Thank you so much for your hard work, it’s an absolute joy working with you.”

In the era of big data in healthcare, the two million member milestone signifies an important step-change in MedShr’s journey. Our newest arm, MedShr Insights, applies natural language processing, machine learning and AI to anonymised case discussions to explore trends in healthcare terms and analyse developments in therapy areas. The MedShr Early Warning System proposal was one of the winners of the Trinity Challenge, with prize funding used to help understand and identify infectious disease outbreaks. Click here to learn more about MedShr Insights and the Early Warning System.

The MedShr team would like to thank our members, Clinical Leaders, Student Ambassadors and partners for believing in our mission to improve patient care by sharing knowledge and experience. We are looking forward to seeing more of your case discussions. If you’re not yet a member of MedShr, join us at medshr.net or download the app on App Store or Google Play.

[ENDS]

Aside Dan

World Leprosy Day – Eliminating Leprosy Worldwide

World Leprosy Day 2022

9 January, 2022

Eliminating leprosy worldwide – MedShr is connecting healthcare professionals globally to share experiences, spread awareness, and end leprosy

World Leprosy Day is on 30th January. Despite the continued reduction in cases and a better understanding of the disease, Leprosy continues to affect the lives of hundreds of thousands of people worldwide. Leprosy is a chronic infectious disease which if left untreated, can lead to life-changing disabilities and have a huge impact on the individual’s quality of life. For many years, people with the disease were isolated and ostracised due to a lack of understanding of the disease. Today, there is an effective treatment and leprosy can be cured.

Each year, around 200,000 people are diagnosed with leprosy. Through improved recognition, diagnosis, and treatment of leprosy, over the past 30 years, there has been a 99% reduction in leprosy cases, highlighting a clear opportunity to eradicate leprosy completely. The Global Partnership for Zero Leprosy (GPZL) is a coalition of individuals and organizations committed to ending leprosy. It builds on existing collaborative networks within the leprosy community to support leprosy programmes with new tools and approaches.

For more than 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy. According to the World Health Organization (WHO), Novartis MDT donations have helped to treat more than 7.3 million patients since 2000. In addition to supporting organisations such as the GPZL, The Novartis Foundation collaborated with Microsoft AI4Health and the Oswaldo Cruz Foundation (Fiocruz) in Brazil on the AI4Leprosy initiative, which aims to develop a screening assistance tool to accelerate leprosy diagnosis

Novartis is also supporting MedShr, a global app and platform for doctors and healthcare professionals, to provide education across a range of infectious diseases, including leprosy. Now with over 1.8M doctors and HCPs, Medshr allows HCPs to share and discuss clinical images and cases for peer-to-peer learning and education. The aim of the MedShr leprosy education program is to increase understanding and awareness of leprosy. MedShr are committed to zero leprosy and support the principles, objectives, and activities of the Global Partnership for Zero Leprosy.

If you’re a doctor or HCP, you can join MedShr’s Infectious Diseases Global Education Network (medshr.it/infectiousdiseases) for free to learn more about leprosy and share and discuss your own experiences.

MedShr also offers free, fast-tracked, registration for medical schools, hospitals, and medical societies. This includes providing private groups for HCPs. Please contact globalhealth@medshr.net to find out more and to make arrangements. You can find out more about leprosy here or read further information below.

What is leprosy and when should you suspect it?

Leprosy is a chronic infectious disease caused by the bacteria Mycobacterium leprae. The disease can affect the skin, mucous membranes, eyes, and some of the peripheral nerves. These are primarily the nerves of the hands, feet, and eyes, and some of the nerves in the skin. In severe, untreated cases, loss of sensation, muscle paralysis of hands and feet, disfigurement, and blindness may occur.

Any patient developing a painless skin discolouration that is either pale or red could be showing early signs of leprosy.

Other symptoms include:

○     Numbness of affected skin

○     Muscle weakness or paralysis

○     Eye problems (these present later in the disease)

Leprosy should be a consideration if your patient has any of these symptoms and they live in an endemic area or someone in their family or close contacts has been diagnosed with leprosy.

How do you treat leprosy?

Multidrug therapy (MDT) has been a major breakthrough in the treatment of leprosy and its improved availability has significantly reduced the global disease burden over the past three decades.

The WHO guidelines recommend a combination of Dapsone, Rifampicin, and Clofazimine. This treatment lasts 6 to 12 months depending on the subtype of leprosy (paucibacillary or multibacillary cases). Since its introduction, more than 16 million leprosy patients have been treated with MDT.

We have the tools and treatment to eliminate leprosy. Through building robust partnerships between organisations, and promoting grassroots education and awareness strategies we believe the goal of eliminating leprosy is within reach.

About MedShr

MedShr is a secure, professional app and network for medical professionals to connect and learn through case discussion. Over two million doctors and HCPs use MedShr to discover, discuss and share clinical cases and medical images. The platform’s innovative educational approach puts focus on the application of insights from the latest scientific publications in real-world scenarios. Developed by doctors, for doctors, it speaks to specialists in their language, fostering learning and discussion about the specifics of clinical decision-making and management.

[ENDS]